Immediate Versus Delayed Switch From Levodopa/Carbidopa to Levodopa/Carbidopa/Entacapone: Effects on Motor Function and Quality of Life in Patients With Parkinson's Disease With End-of-Dose Wearing Off

REFERENCES

• Boiko, A. N., Batysheva, T. T., Minaeva, N. G., Babina, L. A., Vdovichenko, T. V., Zhuravleva, E. Y., Shikhkerimov, R. K., Malykhina, E. A., Khozova, A. A., Zaitsev, K. A., & Kostenko, E. V. (2008). Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial). Neuroscience and Behavioral Physiology, 38, 933–936.
   PubMedGoogle Scholar
• Boomsma, F., Meerwaldt, J. D., Man in't Veld, A. J., Hovestadt, A., & Schalekamp, M. A. (1989). Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: Effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa. Journal of Neurology, 236, 223–230.
   PubMedGoogle Scholar
• Brooks, D. J., Agid, Y., Eggert, K., Widner, H., Ostergaard, K., Holopainen, A., & TC-INIT Study Group (2005). Treatment of end-of-dose wearing-off in parkinson's disease: Stalevo: Levodopa/carbidopa/entacapone and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. European Neurology, 53, 197–202.
   PubMed Web of Science ®Google Scholar
• Brooks, D. J., & Sagar, H. (2003). Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. Journal of Neurology Neurosurgery Psychiatry, 74, 1071–1079.
   PubMed Web of Science ®Google Scholar
• Chapuis, S., Ouchchane, L., Metz, O., Gerbaud, L., & Durif, F. (2005). Impact of the motor complications of Parkinson's disease on the quality of life. Movement Disorder, 20, 224–230.
   PubMed Web of Science ®Google Scholar
• Durif, F., Devaux, I., Pere, J. J., Delumeau, J. C., Bourdeix, I., & F-01 Study Group (2001). Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: An open, multicenter study. European Neurology, 45, 111–118.
   PubMed Web of Science ®Google Scholar
• Fahn, S., Oakes, D., Shoulson, I., Kieburtz, K., Rudolph, A., Lang, A., Olanow, C. W., Tanner, C., Marek, K., & Parkinson Study Group (2004). Levodopa and the progression of Parkinson's disease. The New England Journal of Medicine, 351, 2498–2508.
   PubMed Web of Science ®Google Scholar
• Goetz, C. G., Poewe, W., Rascol, O., & Sampaio, C. (2005). Evidence-based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Movement Disorder, 20, 523–539.
   PubMed Web of Science ®Google Scholar
• Hauser, R. A. (2004). Levodopa/carbidopa/entacapone (Stalevo). Neurology, 62, S64–S71.
   PubMed Web of Science ®Google Scholar
• Heikkinen, H., Varhe, A., Laine, T., Puttonen, J., Kela, M., Kaakkola, S., & Reinikainen, K. (2002). Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose. British Journal of Clinical Pharmacology, 54, 363– 371.
   PubMed Web of Science ®Google Scholar
• Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R., & Hyman, N. (1997). The Parkinson's Disease Questionnaire (PDQ-39): Development and validation of a Parkinson's disease summary index score. Age Ageing, 26, 353–357.
   PubMed Web of Science ®Google Scholar
• Jenner, P. (2003). The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. Parkinsonism & Related Disorders, 9, 131–137.
   PubMed Web of Science ®Google Scholar
• Koller, W., Guarnieri, M., Hubble, J., Rabinowicz, A. L., & Silver, D. (2005). An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. Journal of Neural Transmission, 112, 221–230.
   PubMed Web of Science ®Google Scholar
• Larsen, J. P., Worm-Petersen, J., Sidén, A., Gordin, A., Reinikainen, K., Leinonen, M., & NOMESAFE Study Group (2003). The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease. European Journal of Neurology. 10, 137-146.
   Google Scholar
• Lyons, K. E., & Pahwa, R. (2006). Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (stalevo) in Parkinson disease patients. Clinical Neuropharmacology, 29, 73–76.
   PubMed Web of Science ®Google Scholar
• Miyasaki, J. M., Martin, W., Suchowersky, O., Weiner, W. J., & Lang, A. E. (2002). Practice parameter: Initiation of treatment for Parkinson's disease: An evidence-based review: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 58, 11–17.
   PubMed Web of Science ®Google Scholar
• Morgan, J. P., Bianchine, J. R., Spiegel, H. E., Rivera-Calimlim, L., & Hersey, R. M. (1971). Metabolism of levodopa in patients with Parkinson's disease. Radioactive and fluorometric assays. Archives of Neurology, 25, 39–44.
   PubMedGoogle Scholar
• Müller, T., Erdmann, C., Muhlack, S., Bremen, D., Przuntek, H., Goetze, O., & Woitalla, D. (2006). Pharmacokinetic behavior of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease. Journal of Neural Transmission, 113, 1441–1448.
   PubMed Web of Science ®Google Scholar
• Myllyla, V. V., Kultalahti, E. R., Haapaniemi, H., & Leinonen, M. (2001). Twelve-month safety of entacapone in patients with Parkinson's disease. European Journal of Neurology, 8, 53–60.
   PubMed Web of Science ®Google Scholar
• Myllylä, V. V., Sotaniemi, K. A., Illi, A., Suominen, K., & Keränen, T. (1993). Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. European Journal of Clinical Pharmacology, 45, 419–423.
   PubMed Web of Science ®Google Scholar
• Nutt, J. G., & Fellman, J. H. (1984). Pharmacokinetics of levodopa. Clinical Neuropharmacology, 7, 35–49.
   PubMed Web of Science ®Google Scholar
• Nutt, J. G., Woodward, W. R., Beckner, R. M., Stone, C. K., Berggren, K., Carter, J. H., Gancher, S. T., Hammerstad, J. P., & Gordin, A. (1994). Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology, 44, 913–919.
   PubMed Web of Science ®Google Scholar
• Obeso, J. A., Marin, C., Rodriguez-Oroz, C., Blesa, J., Benitez-Temiño, B., Mena-Segovia, J., Rodríguez, M., & Olanow, C. W. (2008). The basal ganglia in Parkinson's disease: current concepts and unexplained observations. Annals of Neurology, 64, S30–S46.
   PubMed Web of Science ®Google Scholar
• Olanow, C. W., Kieburtz, K., Stern, M., Watts, R., Langston, J. W., Guarnieri, M., Hubble, J., & US01 Study Team (2004). Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Archives of Neurology, 61, 1563–1568.
   PubMed Web of Science ®Google Scholar
• Olanow, C. W., & Obeso, J. A. (2000). Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: Implications for the early use of COMT inhibitors. Neurology, 55, S72–S77; discussion S8–81.
   PubMed Web of Science ®Google Scholar
• Olanow, C. W., Obeso, J. A., & Stocchi, F. (2006a). Continuous dopamine-receptor treatment of Parkinson's disease: Scientific rationale and clinical implications. Lancet Neurology, 5, 677–687.
   PubMed Web of Science ®Google Scholar
• Olanow, C. W., Obeso, J. A., & Stocchi, F. (2006b). Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nature Clinical Practice, 2, 382–392.
   Google Scholar
• Onofrj, M., Thomas, A., Vingerhoets, F., Martin, W., Giménez-Roldán, S., Azulay, J. P., Bernhard, G., Schmidt, W., & Markabi, S. (2004). Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: Results of a large multicentre open-label study. Journal of Neural Transmission, 111, 1053–1063.
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. (1997). Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Annals of Neurology, 42, 747–755.
   PubMed Web of Science ®Google Scholar
• Poewe, W. H., Deuschl, G., Gordin, A., Kultalahti, E. R., Leinonen, M., & Celomen Study Group (2002). Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: A 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurologica Scandinavica, 105, 245– 255.
   PubMed Web of Science ®Google Scholar
• Rao, S. S., Hofmann, L. A., & Shakil, A. (2006). Parkinson's disease: diagnosis and treatment. American Family Physician, 74, 2046–2054.
   PubMed Web of Science ®Google Scholar
• Rinne, U. K., Larsen, J. P., Siden, A., Worm-Petersen, J., & Nomecomt Study Group. (1998). Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology, 51, 1309–1314.
   PubMed Web of Science ®Google Scholar
• Ruottinen, H. M., & Rinne, U. K. (1996a). A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clinical Neuropharmacology, 19, 283–296.
   PubMed Web of Science ®Google Scholar
• Ruottinen, H. M., & Rinne, U. K. (1996b). Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. Journal of Neurology Neurosurgery Psychiatry, 60, 36–40.
   PubMed Web of Science ®Google Scholar
• Schapira, A. H., Emre, M., Jenner, P., & Poewe, W. (2009). Levodopa in the treatment of Parkinson's disease. European Journal of Neurology, 16, 982–989.
   PubMed Web of Science ®Google Scholar
• Silver, D. E. (2004). Clinical experience with the novel levodopa formulation entacapone + levodopa +carbidopa (Stalevo). Expert Review of Neurotherapeutics, 4, 589–599.
   PubMedGoogle Scholar
• Smith, L. A., Jackson, M. J., Al-Barghouthy, G., Rose, S., Kuoppamaki, M., Olanow, W., & Jenner, P., (2005). Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Movement Disorder, 20, 306–314.
   PubMed Web of Science ®Google Scholar
• Stacy, M. (2009). Medical treatment of Parkinson disease. Neurologic Clinic, 27, 605–631.
   PubMed Web of Science ®Google Scholar
• Stalevo® [prescribing information]. (2009). East Hanover, NJ: Novartis Pharmaceuticals Corporation.
   Google Scholar
• Waters, C. H. (1997). Managing the late complications of Parkinson's disease. Neurology, 49, S49–S57.
   PubMedGoogle Scholar
• Weiner, W. J. (2006). Motor fluctuations in Parkinson's disease. Reviews in Neurological Diseases, 3, 101–108.
   PubMedGoogle Scholar
• Welsh, M., McDermott, M. P., Holloway, R. G., Plumb, S., Pfeiffer, R., Hubble, J., & Parkinson Study Group. (2003). Development and testing of the Parkinson's disease quality of life scale. Movement Disorder, 18, 637–645.
   PubMed Web of Science ®Google Scholar